This study was performed to determine the levels of plasminogen activator inhibitor-1 
INTRODUCTION
Elevation of the intraocular pressure (IOP) is recognized as the major causal risk factor for the progression of glaucoma, which is the leading cause of blindness (1) . It is generally accepted that IOP elevation results from an involutional process occurring in the anterior chamber, which obstructs the aqueous outflow (2) . The molecular mechanisms explaining the aqueous flow and IOP are not well understood yet. It is conceivable that the IOP could be controlled in part through genes that are expressed in the eye, specifically in the ciliary body and trabecular meshwork which is involved in the aqueous production and outflow. To this group of genes belongs the gene encoding PAI-1 (3) . PAI-1 is an inducible secreted protein that belongs to the serpin (serine protease inhibitors) superfamily (4) . It constitutes a central component of the fibrinolytic system that maintains the patency of the vascular bed and other vascular structures (5) . PAI-1 is the principle physiological inhibitor of the tissue type plasminogen activator, which specifically converts the inactive zymogen plasminogen into plasmin (6) . The latter is a non specific trypsinlike protease that degrades fibrin and is involved in extracellular proteolysis by degrading matrix components or activating the proenzyme of collagendegrading metallo -proteases
Elevated levels of PAI-1 have been associated with various thrombotic disorders and acute phase response such as after trauma or bacterial infection (8) . PAI-1 gene expression could be enhanced by inflammatory agents such as transforming growth factor B and interleukins (9) . The transforming growth factor (TGF)-ß family of cytokines includes multifunctional proteins that regulate production of a wide variety of gene products, and thus control a wide variety of cellular processes. For example, TGF-ß family members are involved in inflammation, wound healing, extracellular matrix accumulation, bone formation, tissue development, cellular differentiation, and tumor progression (10) . Three mammalian isoforms have been identified to date: TGF-ß1, -ß2, and -ß3, and these isoforms are structurally similar, despite being encoded by different genes (11) . TGF-ß is a cytokine that alters extracellular matrix (ECM) metabolism, and excess ECM has been proposed to increase aqueous outflow resistance in the trabecular meshwork (TM) of glaucomatous eyes (12) . TGF-ß appears to be involved in the pathogenesis of certain forms of glaucoma.
So, the aim of this work is to estimate the aqueous levels of PAI-1, total protein (to evaluate the origin of PAI-1) and TGF ß2 in patients with glaucoma. 
SUBJECTS & METHODS

Statistical analysis:
Data was expressed as mean ±SD. The groups were compared using the Student's-t test .The degree of association between the variables was assessed using Pearson's correlation coefficient (r), where values of p<0.05 were considered significant. Table I shows the mean ±SD of PAI-1 (ng/ml), total protein (ng/ml) and TGFB2 (pg/ml) levels in aqueous of senile cataract patients and glaucoma patients.
RESULTS
There was a significant increase in PAI-1 levels in aqueous of group2 (early primary open angle glaucoma) patients when compared with cataract patients of group1, 4.2±0.33ng/ml and 1.96±0.47 ng/ml respectively (p<0.05). Also there was a significant increase in PAI-1 levels in aqueous humor of group 3 (late primary open angle glaucoma) patients when compared with cataract patients of group1, 5.21±0.38 ng/ml and 1.96±0.47ng /ml respectively (p<0.01). PAI-1 levels were significantly higher in group 3 compared to group 2 (p<0.05).
There was a significant increase in total protein levels in aqueous of group 2 (early primary open angle glaucoma) patients when compared with cataract patients of group1, 77.5±3.8 ug/ml and 52.9±2.3 ug/ml respectively (p < 0.05). Also there was a significant increase in total protein levels in aqueous humor of group 3 (late primary open angle glaucoma) patients when compared with cataract patients of group, 77.9±4.9 ug/ml and 52.9±2.3 ug/ml respectively (p<0.05). No significant difference between group 2 & group 3 was detected.
There was a significant increase in TGFß2 levels in aqueous of group 2 (early primary open angle glaucoma) patients when compared with cataract patients of group1, 3.03±0.41 pg/ml and 1.6±0.12 pg/ml respectively (p < 0.005). Also there was a significant increase in TGFß2 levels in aqueous humor of group 3 (late primary open angle glaucoma) patients when compared with cataract patients (group 1) 4.21±0.3 pg/ml and 1.6±0.12 pg/ml respectively (p<0.05). TGFß2 levels were significantly higher in group 3 compared to group2 (p<0.05).
There was a significant positive correlation between total protein & PAI-1 in both glaucoma groups, r =0.52 (p<0.05) & r=0.8 (p<0.01) ( fig.  1, 2) . Also a significant positive correlation between PAI-1 & TGFß2 was detected in both glaucoma groups, r =0.72 & r=0.67 (p <0.01) ( fig. 3, 4) . 
DISCUSSION
One potential causative factor for the POAG-associated increase in intraocular pressure (IOP) is compromised outflow facility of aqueous humor (AH) through the trabecular meshwork (TM). A disproportionate accretion of ECM occurs in the TM region of POAG eyes, and this buildup is believed to impose greater resistance to AH outflow, resulting in increased IOP (16) . The results of this study demonstrated that the aqueous levels of PAI-1 and total protein were significantly elevated in both glaucoma groups compared to cataract group. Also there was a significant association between the levels of PAI-1 and total protein. This is consistent with the results of Dan et al.
(17) who suggested that enhanced PAI-1 synthesis in the ciliary body may contribute to outflow resistance and IOP elevation.
PAI-1 inhibits the activity of both tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Both tPA and uPA catalyze the conversion of plasminogen into plasmin, a key intermediate in the fibrinolytic cascade. Plasmin, in addition, is known to promote the conversion of certain pro matrix metalloproteinases (MMPs) into their active ECM-degrading forms (18) . This was prompted by the findings of Masos et al (3) who found that in the adult murine eye, the PAI-1 gene is expressed exclusively in the apices of the ciliary body processes and accordingly PAI-1 activity was detected in the aqueous humor . This could be possible for the human eye as it was showed that human ciliary body epithelial cells could express groups of several genes, including genes encoding protease inhibitors (19) . This distinct localization implies that PAI-1 may play a role in the anterior chamber and trabecular meshwork.
Therefore, an increase in PAI-1 levels would be expected to lead to a reduction of activated MMP levels and, conceivably, accumulation of pro-MMPs within responsive tissues. Specifically up regulation of PAI-1 gene in the ciliary epithelium could shift the proteolytic balance towards inhibition and might also interfere with cell adhesion (20) . The subgroup analysis of glaucoma patients showed that PAI-1 levels were highest in patients with late-open angle glaucoma as Dan et al (17) . They found that increased levels of PAI-1 in the aqueous humor glaucoma patients may contribute to sclerosis of the juxtacanilicular tissue and thereby to outflow obstruction and glaucoma pathogenesis (21) . Also, this study has showed significant higher levels of TGF-ß2 in aqueous humor collected from POAG patients compared to cataract patients. . In agreement with these results are Ozcan et al.
(22) and Picht et al. (23) , who postulated that TGF-ß is a cytokine that alters extracellular matrix (ECM) metabolism, and excess ECM has been proposed to increase aqueous outflow resistance in the trabecular meshwork (TM) of glaucomatous eyes. It has been shown that in vitro treatment of cultured human TM cells with TGFß2 leads to changes in gene expression, including genes that may contribute to ECM accumulation (22) . This study showed a positive correlation between TGF-ß2 and PAI-1 in both glaucoma groups which agreed with the findings of Debra et al (24) . They found that TGFß2-treated human TM cells altered the production of the enzymes promatrix metalloproteinase-2 and plasminogen activator inhibitor (PAI)-1. Elevated levels of AH TGFß2 thus may have the dual effect of both a direct increase in TM production of ECM components (e.g., fibronectin) and an enhanced production of gene products inhibiting ECM degradation e.g., PAI-1. The latter has potential effects on ECM accumulation and elevated PAI-1 levels may have other consequences that also contribute to the pathogenesis of glaucoma (19) . It has been reported previously that a progressive loss of human TM cells occurs with normal aging (25) . The rate of this loss appears to be accelerated in POAG eyes. The underlying mechanism(s) for this loss is not yet known although, in addition to a decrease in replicative potential, it has been attributed to a variety of factors that affect TM cell migration and/or adhesion, including increased phagocytosis, oxidative stress, myocilin, and the presence of chemoattractants within the aqueous humor (26) .
Conclusion & Recommendation:
The findings presented in this study suggest that enhanced PAI-1 synthesis in the ciliary body may contribute to outflow resistance and IOP elevation. This raises the possibility of considering intraocular PAI-1 as a target for the design of new glaucoma drugs.
